Inhibiting thrombosis without causing bleeding: can EP3 blockers fulfil the dream?
Institute of Cardiology and Center of Excellence on Aging, 'G. D'Annunzio' University, Chieti, and G. Monasterio Foundation, Pisa, Italy.
Raffaele
R
De Caterina
D000178:Acrylamides / Q000494:pharmacology*; D000818:Animals; D015232:Dinoprostone / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D058308:Receptors, Prostaglandin E, EP3 Subtype / Q000037:antagonists & inhibitors*; D013450:Sulfones / Q000494:pharmacology*; D013927:Thrombosis / Q000188:drug therapy*
C531572:3-(1-((2,4-dichlorophenyl)methyl)-5-fluoro-3-methyl-1H-indol-7-yl)-N-((4,5-dichloro-2-thienyl)sulfonyl)-2-propenamide; D000178:Acrylamides; D010975:Platelet Aggregation Inhibitors; D058308:Receptors, Prostaglandin E, EP3 Subtype; D013450:Sulfones; D015232:Dinoprostone